

Correction: Senzime receives new major order from South Korea and passes 400 delivered TetraGraph

Press release: Uppsala, January 7, 2020. Senzime AB (publ) today announces that they have received a new order of TetraGraph systems and single use electrodes from their distributor in South Korea. The order value amounts to approximately 1,5 MSEK and delivery will take place during the current month. (The correction is editorial)

This is the third large order placed by Senzimes distributor in South Korea since their market launch in August 2019. There are more than 3,000 hospitals in South Korea and more than 700 000 operations are performed annually where anesthesia and muscle relaxants are used.

Senzime's TetraGraph neuromuscular monitor is a unique digital system designed to address the needs of perioperative monitoring of physiologic data in surgical patients receiving general anesthesia and muscle relaxation using neuromuscular blocking drugs (NMBAs). The TetraGraph stimulates a peripheral nerve and measures, analyzes and displays in real-time the muscle function in surgical patients who receive NMBAs as part of their general anesthetic.

Pia Renaudin, CEO of Senzime states, *"It is great to start the new year with a major order that confirms the interest in TetraGraph from doctors as the end-customer sales in South Korea increases. With this order we have delivered over 400 TetraGraph systems to customers in South Korea, Japan, Australia, Sweden, Norway, Denmark, Finland, Switzerland, Spain and Italy. We are looking forward to continuing building our installed base driving sales of TetraSens electrodes."*

For further information, please contact:

Pia Renaudin, CEO of Senzime AB

Tel: +46 (0)70-813 34 17, email: pia.renaudin@senzime.com

TO THE EDITORS

About Senzime

Senzime develops and markets CE- and FDA cleared patient monitoring systems driven by unique algorithms and sensors to closely monitor patients under anesthesia. TetraGraph is a system that digitally and continuously measures the degree of neuromuscular blockade in the patient. The goal is improved clinical precision and simplified management in healthcare. By preventing complications and enabling healthcare professionals to follow guidelines and drug recommendations, TetraGraph can contribute to shorten hospital stays and lower healthcare costs. The vision is a world without anesthesia related complications, where everyone wakes up safely after surgery. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North Growth Market (ticker SEZI). FNCA Sweden AB, +46 (0)8-528 00 399, info@fnca.se is Certified Adviser for Senzime. www.senzime.com

This information is insider information that Senzime AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, on January 7, 2020, 08.45.